FibroGen is developing FG-3019, a fully human monoclonal antibody (MAb) to connective tissue growth factor (CTGF), for the potential treatment of pancreatic cancer. Studies show that abnormally high levels of CTGF are found in pancreatic tumor tissue. Preclinical studies demonstrate that CTGF drives tumor growth and metastasis and that neutralizing antibodies to CTGF effectively stop tumor progression.

Read more about the role of CTGF in cancer and FibroGen's anti-CTGF therapeutic approach.

Development Status
In March 2003, FibroGen was awarded a Phase I Small Business Innovation Research grant from the National Cancer Institute to support the development of new anti-cancer agents targeting CTGF and help to define CTGF's role in cancer.

An Investigational New Drug (IND) application is on file with the FDA to begin clinical testing of FG-3019 in patients with pancreatic cancer.